New Data at the ASCO20 Virtual Scientific Program Reflects Genentech’s Commitment to Accelerating Progress in Cancer Care
Retrieved on:
Thursday, May 7, 2020
Oncology, Health, Clinical trials, Pharmaceutical, Cardiology, Optical, Biotechnology, Medical specialties, Medicine, Immunology, Atezolizumab, Genentech, Immune system, PD-L1, Programmed cell death protein 1, Transitional cell carcinoma, Transitional epithelium, B7, Cancer immunotherapy, Tecentriq (atezolizumab), Alecensa (alectinib), Genentech in Personalized Healthcare, Genentech
Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors.
Key Points:
- Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors.
- Tecentriq is a prescription medicine used to treat adults with:
A type of bladder and urinary tract cancer called urothelial carcinoma. - The approval of Tecentriq in these patients is based on a study that measured response rate and duration of response.
- Continued approval for this use may depend on the results of an ongoing study to confirm benefit.